The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

Malignant Gliomas in Adults

2008 • 3,999 citations

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

2006 • 1,693 citations

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

2008 • 1,335 citations

Blood-brain barrier active efflux transporters: ATP-binding cassette gene family

2004 • 789 citations

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

2002 • 682 citations

The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)

2000 • 528 citations

ABC Transporters and the Blood-Brain Barrier

2004 • 521 citations

Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria

2008 • 474 citations

Receptor tyrosine kinase signalling as a target for cancer intervention strategies.

2001 • 378 citations

The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

2005 • 348 citations

Testing for the equality of area under the curves when using destructive measurement techniques

1988 • 328 citations

Erlotinib (Tarceva, OSI-774) Antagonizes ATP-Binding Cassette Subfamily B Member 1 and ATP-Binding Cassette Subfamily G Member 2–Mediated Drug Resistance

2007 • 299 citations

Drug efflux transporters in the CNS

2003 • 295 citations

Isolation and characterization of human malignant glioma cells from histologically normal brain

1997 • 290 citations

Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux

2002 • 269 citations

P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan

2007 • 264 citations

Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone

2010 • 260 citations

An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016): TABLE 1

2008 • 247 citations

Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux

2010 • 235 citations

The Role of Efflux and Uptake Transporters inN-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions

2008 • 234 citations

Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human

2009 • 226 citations

Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

2008 • 217 citations

P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib

2009 • 191 citations

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

2010 • 176 citations

Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

1999 • 173 citations

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

2009 • 169 citations

Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters

2009 • 156 citations

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

2006 • 143 citations

Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds

2008 • 140 citations

Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein

2004 • 119 citations

Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3

2010 • 114 citations

Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study

2008 • 113 citations

Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors

2007 • 99 citations

Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design

2008 • 82 citations

Sorafenib exerts anti-glioma activity in vitro and in vivo

2010 • 81 citations

Experience with sorafenib and adverse event management

2010 • 72 citations

Breast Cancer Resistance Protein Interacts with Various Compounds in Vitro, but Plays a Minor Role in Substrate Efflux at the Blood-Brain Barrier

2009 • 69 citations

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

2010 • 64 citations

An extension of satterth waite's approximation applied to pharmacokinetics

1998 • 60 citations

Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma

2011 • 42 citations

Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05–02)

2009 • 40 citations

In Vitro to In Vivo Comparison of the Substrate Characteristics of Sorafenib Tosylate toward P-Glycoprotein

2010 • 40 citations

Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05–02)

2009 • 20 citations

A phase I trial of sorafenib (BAY 43–9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)

2007 • 18 citations

[Regrowth patterns of glioma--cases of glioma regrew away from the original tumor].

1989 • 11 citations